Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03152552 · ClinicalTrials.gov registry record · Phase 2
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT03152552 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 125 participants.
The verdict
NCT03152552, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
Interventions
- DRUG Placebo
- DRUG Empagliflozin
- DRUG LIK066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2017-07-25 |
| Est. Completion | 2018-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03152552
The ClinicalTrials.gov registry entry for NCT03152552 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03152552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03152552 about?
NCT03152552 is a clinical study titled "A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure". This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
What is the current status of trial NCT03152552?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2017-07-25. Estimated completion is 2018-06-06.
What interventions are being tested in trial NCT03152552?
The interventions under investigation include: Placebo (DRUG), Empagliflozin (DRUG), LIK066 (DRUG).
Who is sponsoring clinical trial NCT03152552?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.